We read with great interest the paper from Glintborg and coauthors ‘To switch or not to switch’ reporting biosimilar etanercept switching in Denmark.1 In the Danish Biologic (DANBIO) cohort, patient treated with originator etanercept (Enbrel) were informed of a mandatory switch to SB4. However, the 25 mg pen or a powder-based preparation of original etanercept (OE) were still available. At 1 year after this decision, the authors reported that only 79% of patients had switched to SB4 and 21% remained treated with the originator biologic. In westernised countries, biologics therapies …

中文翻译：

---

“转换还是不转换”：生物仿制药难题中的缺失部分？

我们非常感兴趣地阅读了 Glintborg 和合著者的论文“转换或不转换”报告丹麦生物仿制药依那西普转换。1 在丹麦生物 (DANBIO) 队列中，接受原研药依那西普 (Enbrel) 治疗的患者被告知强制转换到SB4。然而，25 毫克笔或原始依那西普 (OE) 的粉末制剂仍然可用。在做出这一决定后的 1 年，作者报告说，只有 79% 的患者转用了 SB4，21% 的患者仍然使用原研生物制剂进行治疗。在西方国家，生物制剂疗法……